Vendor Intelligence Report: Homopeptide

Published 3 Jul 2026. 26-page investigative report on who is behind Homopeptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 15 Finnrick lab tests, Homopeptide’s overall pass rate is 80% (12 pass / 3 fail). The pattern is not vendor-wide collapse: Retatrutide is the clear relative bright spot, Tirzepatide looks serviceable until the identity-failure caveat is considered, and Tesamorelin is the weak line. For this vendor, peptide-by-peptide signal matters.

The non-lab investigation is sharper. Homopeptide’s active storefront points into a trust ecosystem that appears self-contained: verifier-like sites, a rating/community layer, and newly registered domains resolve back into the same infrastructure set rather than standing apart as independent checks. Claimed Janoshik support and trade-publication awards do not verify cleanly as buyer-safety credentials.

Corporate identity is anchored to a China-based commercial network, with Hunan Aslsen Technology Co., Ltd. appearing as the main company lead, but the natural-person ownership and domestic registry layer remain unresolved. Contact routing is equally messy: Telegram, WhatsApp, forum aliases, and rotating sales names create room for impersonation and payment diversion.

For a buyer already considering Homopeptide, the practical read is conditional rather than binary. Retatrutide is the only line with a stronger current Finnrick signal; Tirzepatide needs lot-level confirmation after a severe identity miss; Tesamorelin should be avoided unless independent batch evidence overrides the vendor history. Ratings also shrink under stricter purity and fill assumptions.

Inside the full report:

  • Appendix A per-product Finnrick data and methodology-divergence charts for all 3 products
  • DNS, RDAP, and IP mapping of Homopeptide-linked verifier and community domains
  • Corporate-identity analysis covering Hunan Aslsen, Chengdu leads, and unresolved ownership
  • Exhibits for the Janoshik database search, storefront captures, and award-claim review
  • Contact, impersonation, Airtm payment, warehouse, customs, and batch-traceability analysis

Risk assessment

  • Tesamorelin and Tirzepatide product-quality risk — high: Tesamorelin is 4 tests, 2 pass / 2 fail, 46.92%; Tirzepatide is 5 tests, 4 pass / 1 fail, 79.11%, with the failed sample described as containing no Tirzepatide.
  • Fake-verification and credential-integrity risk — high: Homopeptide.net, PeptideMeter, CompoundTalk, VendorInvestigate, Medutest, and TheGLPLounge resolve to 101.99.94.39; Janoshik and award claims did not verify as independent safety credentials.
  • Brand-confusion, impersonation, and payment-channel risk — high: Rotating Telegram/WhatsApp personas, Reddit impersonation reports, PeptideCentral scam/fake alerts, and Airtm payment reports create a high-risk buying environment.
  • Controlled-precursor sales and manufacturing-governance risk — high: Hunan Aslsen, the corporate anchor identified for Homopeptide, appears in B2B records listing BMK/PMK precursor chemicals; no direct peptide contamination was found, but injectable-chain segregation is unverified.
  • Batch-traceability and endotoxin-visibility risk — medium: Field-reviewed Homopeptide samples lacked usable batch IDs and no endotoxin testing data was located, limiting lot tracing if a contamination issue emerges.
  • Customs-interception and logistics-transparency risk — medium: Local-warehouse and “100% pass delivery” claims are unverified, while CBP’s 2026 seizure record shows active enforcement against similar unapproved peptide parcels.